Abstract
In multiple myeloma (MM), biologic complexity originates from complex oncogenic processes involving somatic acquisition of myriad mutations coupled with genetic variability within the host. This pathogenically determined molecular heterogeneity predetermines clinical intricacy. In this study, we performed gene expression profiling (GEP) focusing on centrosome-related genes to determine the molecular heterogeneity for centrosome-associated genes in patients with MM. We identified the gene pattern with an impact on myeloma pathogenesis. According to expression tendency, three subgroups of patients were established. The revealed molecular signature is related to overall survival as well as to clinical parameters and the International Staging System. Associations with integral clinical parameters allow us to proclaim the impact of the revealed functional gene set in MM genesis. We believe that future investigation of this molecular heterogeneity will help to refine the broad prognoses offered by present-day established systems and even sub-stratify them.
Acknowledgements
We would like to thank all the patients who participated in this study. We would like to thank John B. Smith for proofreading the manuscript.
Potential conflict of interest:
Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.
This work was supported by grants from the Internal Grant Agency of The Ministry of Health: NS10207, NT11154, NT12130, NT13190; a grant from The Ministry of Education, Youth and Sports: MSM0021622434; a project GAP304/10/1395 of The Czech Science Foundation; and by a project (Ministry of Health, Czech Republic) for conceptual development of research organization 65269705 (University Hospital Brno).